Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 5/20 | 0.47 |
| ▸ | GSK3B | P49841 | 4/20 | 0.44 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.41 |
| ▸ | FLT1 | P17948 | 3/20 | 0.41 |
| ▸ | KDR | P35968 | 3/20 | 0.41 |
| ▸ | BCHE | P06276 | 2/20 | 0.40 |
| ▸ | BACE1 | P56817 | 2/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.39 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22925909 | 1.00 | ACHE (0.47) | ACHEGSK3BSPHK2HDAC1NPSR1 | |
| SCHEMBL29620989 | 0.86 | GSK3B (0.55) | ACHEGSK3BHDAC1NPSR1BCHE | |
| SCHEMBL22925908 | 0.86 | GSK3B (0.55) | ACHEGSK3BHDAC1NPSR1BCHE | |
| SCHEMBL22925921 | 0.82 | VCP (0.46) | FLT1KDR | |
| SCHEMBL29620940 | 0.82 | VCP (0.46) | FLT1KDR | |
| SCHEMBL29621004 | 0.76 | ACHE (0.49) | ACHEGSK3BNPSR1ROCK2FLT1 | |
| SCHEMBL23452011 | 0.72 | BCHE (0.59) | ACHEHDAC1NPSR1BCHEBACE1 | |
| SCHEMBL21439829 | 0.72 | NPSR1 (0.47) | ACHEGSK3BNPSR1FLT1KDR | |
| SCHEMBL21327565 | 0.69 | HDAC1 (0.52) | HDAC1HDAC6 | |
| SCHEMBL22925920 | 0.68 | KDR (0.47) | FLT1KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12448371-B2 | Inhibitor compounds | Cincera Therapeutics Pty Ltd (AU) | 2025-10-21 | — | — | US | claimed |
| CN-114450281-B | Inhibitor compounds | 辛塞拉治疗私人有限公司 | 2024-08-16 | — | — | CN | claimed |
| EP-4003986-A1 | INHIBITOR COMPOUNDS | Cincera Therapeutics Pty Ltd (AU) | 2022-06-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12448371-B2 | Inhibitor compounds | SERPINB1, MMP1, SSB | ACHE 3297/4885GSK3B 605/4885SPHK2 1491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.